Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna

Executive Summary

Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.

Advertisement

Related Content

Scandinavia Serves Up Two Partners For Alexion, In Its Rare Disease Sweet-Spot
Cerevel Launches With Pfizer's Early CNS Assets And $350m From Bain Capital
Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions
Microbiome Offers Rich Pickings As Takeda Becomes Enterome's Second Big Pharma Crohn's Partner
Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune
AbbVie To Take Flight From Galapagos As PELICAN Flounders?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124053

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel